期刊文献+

N-三甲基壳聚糖包衣胰岛素眼用纳米脂质体的研制 被引量:3

Study on the Preparation of Insulin Nanoliposomes Coated by N-trimethyl Chitosan
下载PDF
导出
摘要 目的:制备N-三甲基壳聚糖(TMC)包衣胰岛素眼用纳米脂质体(INSL),筛选最优处方。方法:采用逆向蒸发法制备INSL,并用季铵化程度为60%的TMC(TMC60)对其进行包衣。以包封率为主要指标,用正交试验筛选最优处方,并对其相关体外性质进行考察。结果:TMC60包衣INSL的最优处方组成为:药脂比为1:50,胆固醇与卵磷脂之比为1:4,TMC60的最佳浓度为4 mg·ml^(-1);最佳旋蒸温度为15℃。最优处方的平均包封率为(59.17±1.46)%(n=3)。未包衣的INSL的平均粒径为(88.97±0.46)nm,Zeta电位为(-30.5±0.46)mV。TMC60包衣后,平均粒径为(91.33±0.06)nm,Zeta电位为(29.47±0.15)mV。结论:TMC60包衣INSL的包封率较高,表面带有较高的正电位,为研究其眼部释药系统奠定了实验基础。 Objective:To prepare insulin nanoliposomes(INSL) coated by N-trimethyl chitosan(TMC) and screen the optimal formula.Method:INSL were prepared by the reverse evaporation method,and TMC with 60%degree of quarternization(DQ) (TMC60) was used as the coating material.The encapsulation efficiency as the index,the optimal formula of the preparation was screened using the orthogonal experiment,and the characteristics in vitro of the preparation were investigated.Result:The optimal formula of the TMC60-coated INSL was as follows:the ratio of drug and lipid was 1:50,the ratio of cholesterol and lecithin was 1:4,and the optimum concentration of TMC60 was 4 mg · ml^(-1) with 15℃as the rotary evaporation temperature.The mean entrapment efficiency of the optimal TMC60-coated INSL was(59.17±1.46)%(n = 3).The mean diameter of INSL before the coating was(88.97±0.46) nm,and the Zeta potential was(-30.5±0.46) mV.The mean diameter of INSL after TMC60-coating was(91.33±0.06) nm,and the Zeta potential was(29.47±0.15) mV.Conclusion;The encapsulation efficiency and the positive Zeta potential of the preparation are promising,which can provide experimental foundation for the further study of the ophthalmic drug release system.
作者 何文 周晶晶
出处 《中国药师》 CAS 2012年第12期1671-1674,共4页 China Pharmacist
关键词 N-三甲基壳聚糖 胰岛素 脂质体 包衣 逆向蒸发法 N-trimethyl chitasan Insulin Liposomes Coating Reverse evaporation method
  • 相关文献

参考文献13

  • 1侯振清 张镇西.胰岛素制剂的历史演变及发展状况[J].中华医药杂志,2004,4(7):619-622.
  • 2Robinson JR,Mlynek GM.Bioadhesive and phase-change polyrners for ocular drug delivery[J].Adv Drug Deliv Rev,1995,16:45-50.
  • 3Meisner D,Mezei M.Liposome ocular delivery systems[J].Adv Drug Deliv Rev,1995,16:75-93.
  • 4韩晓,王东凯,王玉.新型给药系统的研究进展[J].中国药剂学杂志,2009,7(2):59-64.
  • 5冯敏,何文.眼用维生素A棕榈酸酯阳离子脂质体-原位凝胶的研制及体外释药研究[J].中国药师,2010,13(5):631-634. 被引量:12
  • 6Rabinovich GL,Couvreur P,Lambert G,et al.Cationic vectors in ocular drug delivery[J].J Drug Trget,2004,12:623-633.
  • 7Cortesi R,Argnani R,Esposito E,et al.Cationic liposomes as potential carriers for ocular dministration of peptides with antiherpetic activity[J].Int J Pharm,2006,317:90-100.
  • 8Jonker C,Hamman JH,Kotze AF.Intestinal paracellular permeation enhancement with quaternised chitosan:in situ and in vitro evalution[J].International Journal of Pharmaceutics,2002,238:205-213.
  • 9吴正红,平其能,张磊,郭建新,魏毅,赖家明.反相高效液相色谱法测定多糖包覆脂质体中胰岛素[J].药物分析杂志,2002,22(6):425-427. 被引量:14
  • 10吴正红,平其能,雷晓敏,陈燕.TMC包覆胰岛素脂质体的研究[J].中国药学杂志,2003,38(9):678-682. 被引量:9

二级参考文献53

  • 1邓富良,周平,陈本美,邓世林,梁绍先,陈国华,周其伟.高效液相色谱法测定维康胶囊中维生素A,D_2,E的含量[J].中国药学杂志,2004,39(10):784-785. 被引量:6
  • 2高斐,王东凯,罗立,徐松林,刘莱,徐飒.左氧氟沙星热敏型眼用凝胶的研制及体外释放研究[J].中国药房,2005,16(14):1057-1059. 被引量:42
  • 3Robinson JR,Mlynek GM.Bioadhesive and phase-chenge polymers for ocular drug delivery[J].Adv Drug Deliv Rev,1995,16:45-50.
  • 4Meisner D,Mezei M.Liposomc ocular delivery systems[J].Adv Drug Dellv Rev,1995,16:75-93.
  • 5Rabinovich-Guilatt L,Couvreur P,Lambert G,et al.Catiohie vectors in ocular drug delivery[J].J Drug Target,2004,12:623-633.
  • 6Cortesi R,Argnani R,Esposito E,et ak.Calionic liposomes as potential carriers for ocular administration of pep tides with antiherpetic activity[J].Int J Pharm,2006,317:90-100.
  • 7Desai SD,Blanchard J.In vitro evaluation of p luronic F127-based controlled relese ocular delivery systems for pilocarp ine[J].J Pharm Sci,1998,87:226-230.
  • 8Lederer CM Jr,Harold RE.Drop size of comer cialglaucoma medications[J].Am J Ophthalmol,1986,101(6):691.
  • 9MeCaffrey PG, Perrino BA, Soderling TR, et al. NF-ATP, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs[J]. J Biol Chem, 1993, 268(5): 3747 -3752.
  • 10Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery[J]. Adv Drug Deliv Rev, 1995, 16: 45-50.

共引文献86

同被引文献41

  • 1高斐,王东凯,罗立,徐松林,刘莱,徐飒.左氧氟沙星热敏型眼用凝胶的研制及体外释放研究[J].中国药房,2005,16(14):1057-1059. 被引量:42
  • 2张翠霞,张文涛,王东凯,仲静洁,徐飒.新型的药物传递系统-原位凝胶的研究进展[J].中国医院药学杂志,2006,26(4):459-461. 被引量:42
  • 3韩晓,王东凯,王玉.新型给药系统的研究进展[J].中国药剂学杂志,2009,7(2):59-64.
  • 4ROBINSON J R, MLYNEK G M. Bioadhesive and phase- change polymers for ocular drug delivery [ J ]. Adv Drug Deliv Rev, 1995,16:45 - 50.
  • 5MEISNER D, MEZEI M. Liposome ocular delivery systems [J]. Adv Drug Deliv Rev,1995,16:75 -93.
  • 6RABINOVICH GL, COUVREUR P, LAMBERT G, et al. Cationic vectors in ocular drug delivery [ J ]. J Drug Trget, 2004,12:623 - 633.
  • 7CORTESI R, ARGNANI R, ESPOSITO E, et al. Cationic liposomes as potential carriers for ocular dministration ofpeptides with antiherpetic activity [ J ]. Int J Pharm, 2006, 317:90 - 100.
  • 8JONKER C, HAMMAN J H, KOTZE A F. Intestinal paracellular permeation enhancement with quatemised chitosan:in situ and in vitro evalution [ J ]. Int J Pharm, 2002,238:205 - 213.
  • 9TANG Yufeng, DU Yumin, HU Xianwen. Rheological characterisation of a novel thermosensitive chitosan/poly (vinyl alcohol) blend hydrogel [ J ]. Carbohyd Polym, 2007,67 (4) :491 - 499.
  • 10DESAI S D, BLANCHARD J. In vitro evaluation of pluronic F127-based controlled release ocular delivery systems for pilocarpine [ J ]. J Pharm Sci, 1998,87:226 -230.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部